We are an innovative biotechnology company engaged in the discovery and development of life-improving drug therapies to treat rare and complex central nervous system, or CNS, disorders, including narcolepsy, idiopathic hypersomnia, or IH, and other rare sleep disorders, as well as neurodevelopmental disorders, such as Attention Deficit Hyperactivity Disorder, or ADHD. Pharmaceutics Ltd. is offering units, or Units, each consisting of one of our common shares and one Warrant to purchase one of our common shares, or, each, a Warrant, in an initial public offering.
We are a revenue stage medical technology company focused on the development and commercialization of a highly differentiated technology offering a clinically effective non-surgical, non-invasive, non-pharmaceutical, and low-cost solution for patients with sleep disordered breathing (SDB), including mild-to-moderate obstructive sleep apnea (OSA).
Airbnb has enabled home sharing at a global scale and created a new category of travel.
PGIM Short Duration High Yield Opportunities Fund, a Maryland statutory trust (the "Fund"), is a newly organized, diversified, closed-end management investment company. The Fund's investment objective is to provide total return, through a combination of current income and capital appreciation. There can be no guarantee that the Fund will achieve its investment objective or be able to structure its investment portfolio as anticipated.
Follow-On Uplisting: We are offering 1,500,000 units (each a “Unit”), each Unit consisting of one share of common stock, par value $0.0001 per share, and one warrant (each a “Warrant”) at an assumed price of $4.75 per Unit. Each Warrant is immediately exercisable, will entitle the holder to purchase one share of common stock at an exercise price of $5.70 and will expire five (5) years from the date of issuance. The shares of common stock and Warrants may be transferred separately immediately upon issuance. Our application for listing of our common stock and Warrants on The Nasdaq Capital Market has been approved subject to notice of issuance.
FOLLOW-ON OFFERING: We are a biopharmaceutical company headquartered in Edison, New Jersey, focused on the development of pleiotropic drug therapy for treatment of chronic liver disease.
HF Enterprises Inc. is a diversified holding company principally engaged through its subsidiaries in property development, digital transformation technology and biohealth activities with operations in the United States, Singapore, Hong Kong, Australia and South Korea.
We are in the business of designing and manufacturing electric outboard powertrain systems and our related technology.
*Special terms and conditions: IPO of OZON will take place on the American stock exchange Nasdaq with the expected trading date of November 24. Issued American Depositary Shares (ISIN US69269L1044) will be also listed on the Moscow Exchange, so that the stock will be simultaneously traded on the Nasdaq and MOEX. Once the shares are allocated to the client's account, the instrument will be quoted in Russian rubles and by closing the position (selling shares) the client will make a trade on the Moscow Exchange with settlement in rubles.
The minimum order volume is 2000 USD, the LockUp period without the possibility of early sale is 4 trading days (can be increased).
LifeSci Acquisition II Corp., which we refer to as “we,” “us” or “our company,” is a newly organized blank check company incorporated in Delaware and formed for the purpose of entering into a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization or other similar business combination with one or more businesses or entities, which we refer to throughout this prospectus as our “initial business combination.” Although we are not limited to a particular industry or geographic region for purposes of consummating an initial business combination, we intend to focus on businesses that have their primary operations located in North America in the healthcare industry.
Unit Offering Consisting of One Share of Common Stock and One Series A Warrant to Purchase One Share of Common Stock. Auddia has developed technology, utilizing Artificial Intelligence (“AI”), to enable consumers to listen to existing AM/FM radio stations without commercials. By leveraging our legacy platform that served the commercial radio industry for seven years, and by deploying new artificial (AI) technologies that can identify and segment different units of audio content, we plan to bring to market a premium, subscription-based AM/FM radio listening experience through a downloadable app called AuddiaSM (the “Auddia App”).
Develops, designs and manufactures disinfection systems, that eliminate pathogens that may cause healthcare-acquired infections (“HAIs”),
We are a cutting-edge wellness hemp-derived cannabidiol, or CBD, consumer product development company. We are in the early stage of manufacturing, distributing, and marketing a diverse line of consumer products infused with CBD. We are offering 1,000,000 units (each, a “Unit”), each Unit consisting of one share of common stock, par value $0.001 per share, and one warrant (each a “Warrant”), in a firm commitment initial public offering at an assumed price of US$7.50 per Unit.
The offering price is determined by the underwriter and is normally based on numerous factors such as company’s financials, its future perspectives and risks, as well as demand for the company shares.The price determined should be high enough for the company to raise sufficient capital, while representing a fair value of the shares for potential investors.